CO-FOUNDER AND BOARD MEMBER
Johan has a Ph.D. from Karolinska Institutet with a focus on neuropharmacology and with significant international academic and industrial experience in the area of Neurology. After his academic years he began working at AstraZeneca’s CNS unit in Södertälje in 2003, where he held scientific, project and executive positions in charge of in vitro biology, in vivo pharmacology and biochemical biomarkers within the CNS field. With AstraZeneca’s exit from the CNS area in 2012, Johan and a number of colleagues founded AlzeCure, where he has worked since. As CEO until 2020, AlzeCure went through several financing rounds and eventually became a publicly traded company in November 2018. He is currently the CSO of the company.